Result of Interim Analysis of Overall Survival in the GCIG ICON7 Phase III Randomized Trial of Bevacizumab in Women with Newly Diagnosed Ovarian Cancer
Assessing Response and Progression in Ovarian Cancer Clinical trials RECIST 1.1 and CA125 Criteria E.A. Eisenhauer GCIG Ovarian cancer clinical trials planning meeting
Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer MW Audeh,1 RT Penson,2 M Friedlander,3 B Powell,4
High RR and long PFS in phase II studies and retrospective ... P90, C AUC4. Day 1, 8, 15 q28 x2. 53. 10. 13. Van der Burg 2004. P80, C AUC 2. Day 1, 8, 15 q28 ...
Symptom control in patients with recurrent ovarian cancer Measuring the benefit of palliative chemotherapy in women with platinum refractory/ resistant ovarian cancer
Consolidation Therapy and Management of Isolated Marker Relapses in ... Angiolo G. Oncology/Hematology 2005. CONSOLIDATION RADIOTHERAPY. 5 years OS. 5 years PFS ...
State of the Art Therapy. 6-12 Months Post Platinum-Based Therapy. Thomas Herzog, MD ... Chemotherapy Options for Platinum Intermediately Sensitive ROC ...
Treatment of Ovarian Cancer 21st Century and Beyond Judith K. Wolf Professor Gynecologic Oncology Judith K. Wolf, MD Professor Department of Gynecologic Oncology ...
UNANSWERED QUESTIONS IN UPFRONT THERAPY CHEMOTHERAPY ISSUES: WEEKLY DOSING Andr s Poveda, MD Fundaci n Instituto Valenciano de Oncolog a apoveda@fivo.org
The role of adjuvant chemotherapy in surgical stage I-II serous or clear cell ... MITO: New adjuvant trial comparing sequential CT RT, as standard arm, versus CT ...
Randomised EORTC-GCG/NCIC-CTG trial on NACT IDS versus PDS. Surgical characteristics (PP1) ... no bulky lymph nodes. Endpoints: OS, PFS, QoL Strata: centre, PS ,age ...
transfusions and use of growth factors. 2004 International ... New Zealand), EORTC (Europe), GEICO (Spain), GINECO (France), NSGO (Scandinavia), JGOG (Japan) ...
History of IP chemotherapy in OC. Indications for IP chemothrapy ... 2001 : IP therapy: a sacrifice bunt (McGuire) 2002 : IP therapy: a therapy whose time has come ...
4. Cell-survival pathways. Cyclin-dependent kinases, mTOR, cGMP, COX-2, p53, Bcl-2 ... EBRT 45-50 Gy EB or BT. total dose point A 85 Gy. R. A. N. D. O. M. I. Z ...
... of Literature, Translation, Astrology, Meteorology, and especially Vajrayana ... Additional studies such as Astrology and Traditional Tibetan Medicine, including ...
Through his dedication and support the Ngakpa Tradition grew all over Tibet. ... Tibetan women are recognized as one of the largest contributors to the Ngakpa ...
Trial Concept Weekly VS Three Weekly Chemotherapy for Chemoradiation in Cervical Cancer Dr Sarikapan Wilailak* * Endorsed by the TGCS (Thai Gynecologic Cancer Society)
Efficient Designs for Phase II and Phase III Trials Jim Paul CRUK Clinical Trials Unit Glasgow Efficient Getting it wrong:- Efficient design for phase II trials Phase ...
NSGO Genomic study coordinator Elisabeth vall Lundqvist. Coordinator BMS/CCK ... In case of withdrawal (ineligibility, pts request) fill in Withdrawal form ...